MONOMERIC CALCITONIN (CT) DEFICIENCY I N PATIENTS WITH CONGENITAL NON GOITROUS HYPOTtlYROIDISM (CH) DURING EARLY INFANCY. CT d e f i c i e n c y h a s been r e p o r t e d i n c h i l d r e n and a d o l e s c e n t s w i t h
Cll;bbt whether i t i s a l s o deficient i n CH p a t i e n t s d u r i n g i n f a n c y h a s n o t been i n v e s t i g a t e d . Plasma e x t r a c t i o n of CT has much improved t h e s e n s i t i v i t y and s p e c i f i c i t y of CT radioimmunoassays f o r t h e measurement o f t h e monomeric CT form, t h e a c t i v e form of t h i s hypocalcemic hormone. To f u r t h e r analyze CT s e c r e t i o n i n e a r l y infancy, we measured CT and Calcium (Ca) v a l u e s i n I) normal i n f a n t s aged 0-2 y r s ( g r . NL-I, n-39) and 2-5 y r s ( g r . NL-2, n=12) and 2) CH i n f a n t s aged 0-2 y r s ( g r . CH-I, n=6) and 2-5 y r s ( g r . CH-2,n=6) R e s u l t s a r e shown i n -t h e ;able (Mean 2 SEM):( XX p<O,OI a s compa r e d t o groups NL) gr.NL-l gr.CH-l I g r .NL-2 g r . CH-2 CT(pglm1) 12.86+1.12 3 . 2 3 2 0 . 6 3~~ 6.4821 . I 6 1 . 2 5 + 0 . 0 6~~ Ca(mg/dl) 9.73t0.09 9.73t0.20 9.65+0.08 9.5720.11 The d a t a show t h a t CT v a l u e s -I ) d e c r e a s e d u r i n p t h e f i r s t y e a r s o l i f e i n b o t h normal and CH p a t i e n t s , and 2) a r e lower i n CH than i n normal s u b j e c t s . I n conclusion: 1) low b u t d e t e c t a b l e v a l u e s o CT a r e p r e s e n t i n CH p a t i e n t s , i n d i c a t i n g t h a t f u n c t i o n a l c a l c i t o n i n s e c r e t i n g c e l l s do e x i s t i n t h e s e p a t i e n t s ; 2) t h e low CT l e v e l s i n i n f a n t s w i t h CH a s compared w i t h normal s u b j e c t s sugges t h a t CT d e f i c i e n c y could have an important pathogenic r o l e i n t h e hypercalcemia o c c a s i o n a l l y observed i n CH p a t i e n t s d u r i n g t h e n e o n a t a l p e r i o d .
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Hypercalcemia has been described in infants with CH before and after treatment with Thyroxine (T4). In a group of 25 infants, hypercalcemia during T4 therapy was related to vit D supplementation (in France 1200iu/d). To study further adequate vit D dosage to maintain normal Ca levels, 2 groups of infants were studied during the first 6 months of life. Group I (n=5) without and Group I1 (n=10) with 400 iu/d of vit D. Serum Ca (mg/dl +SEM) and 250HD were measured at diagnosis (<lmonth) before treatrent, and at 2, 4 and 6 months of life. To e x p l o r e t h i s , we s t u d i e d thc h a l f -l i f e o f a-FP d u r i n g t h e f i r s t month of l i f e i n neonates wit1 CH and neonates w i t h t r a n s i e n t hyperthyrotropinaemia (TH), which we considered a s t h e c o n t r o l group. Between t h e 3 r d and 7 t h day of l i f e a-FP was measured i n 6 0 c a s e s with CH with a mean g e s t at i o n a l age of 39.9t1.5 weeks ard i n 184 c a s e s with TH with a mean g e s t a t i o n a l a g e of-39.3+1.9 weeks. The mean l o g a-FP l e v e l s i n t h e two groups were 4.3$+_0.39ng/ml and 3.97t_0.36ng/ml r e s p e c t i v e l y (p <0.01). Levels of a-FP were a l s o measured i n 6 1 c a s e s with Ctl a t a mean age of 29.8t12.9 d a y s and i n 37 c a s e s with TH a t a mean a g e of 36.5t13.1 d a y s . The r e s p e c t i v e mean v a l u e s of l o g a-FP were 3.84+0r46ng/ml and 2.71+0.55ng/ml,after adjustment f o r c o n c e p t i o n a l a g e d i f f e r e n c e s ( p < 6,001). The half -l i f e of a-FP was 15.7 d a y s f o r t h e CH group and 7.7 d a y s f o r t h e TH group. Th I i a l f -l i f e of a-FP was a l s o c a l c u l a t e d i n each of 3 9 c a s e s with CH and 8 c a s e s with TH f o r which t h e r e were s e r i a l measurements of a-FP. The half -l i f e of a-FP i n t h e two groups was 12 d a y s and 4 . 9 days, r e s p e c t i v e l y . W e conclude t h a t catabolism of a-FP i s d e l a y e d i n CH group, r e s u l t i n g i n inceased serum l e v e l s of a-FP. The l a c k of t h y r o i d hormones, and e s p e c i a l l y of T3, is probably r e s p o n s i b l e f o r t h a t .
METHODS FOR BONE MATURITY ASSESSMENT TO EVALUATE PRENATAL HYPOTHYROIDISM.
Delayed skeletal.maturation in newborn infants wit congenital hypothyroidism (CH) is considered t reflect the degree of intrauterine hormone def icien cy. Bone development was assessed by X-ray during th first month of life in 63 infants who had positiv screening tests for CH. Serum hormone analysis con firmed the diagnosis in 46 infants while the remainin 17 infants were euthyroid at follow-up. Therapy wa initiated in CH patients at the same age as radiogram were taken: 14.5f5.7 (xfSD) vs 15.0f5.5 days. Fiv radiographic methods to assess skeletal. developmen (including SBnecal et al. (Arch Fr Ped. 34 (1977) 424 were tested for their capacity to distinguish C patients from euthyroid infants. The various method involved assessment of the shape and size of ossifica tion centers in the knee and ankle regions. All fiv methods revealed statistically significant retarde J.Alm*(lntrod. by M.Ritzen).
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THYROXIN ( i 4 ) EFFECTS ON GROWTH AND l1EPATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGF) ONTOCENY IN MICE WITH CONGENITAL HYPO-
I -
THYROIDISM (CH).
The effects of thyroid hormones on growth and development are probably mediated by specific growth factors as EGF. We have studied the effects of thyroxine on growth and hepatic EGF receptor ontogeny in a mouse strain with an inherited form of CH. Hypothyroid mice (hjh) were treated with T4 between day 20 and day 40 postnatally, h/h nontreated mice and euthyroid (+/+) mice served as controls.
Animals were killed at day 20 or day 40 postnatally. Serum thyroxine was measured by RIA and EGF receptor binding in a liver plasma-membrane homogenate. Up to 20 days of age all mice showed the same weight gain and EGF hepatic receptor binding were low and not significantly different between h/h and +/+ mice. From day 20 h/h mice had a significantly lower growth rate than + I t mice, a growth retardation that were normalised by T4 treatment. Old data seems to indicate that ectopic thyroids involuate after several years of TSH suppression by T4 treatment. This work was undertaken to study the secretion of thyroid hormone (M) and thyroglobulin (Tg) by remnant thyroid tissue. In 16 children with congenital hypothyroidism (CHI due to ectopic gland, aged 7.lt0.5 yrs (range 5-11.5 yrs), s e m TSH, FT4, FT3 and Tg were measured under adequate LT4 therapy (phase I) and after 4 weeks of LT4 deprivation (phase 11). Informed In phase I Tg was detectable in 8/16 patients which indicates that some thyroid secretion occurs in treated patients. Tg levels increase in phase I1 (range 6 to 50 ng/ml) which demonstrates in all cases the presence of actively secreting remnant tissue responsive to TSH stimulation. The low levels of FT4 and FT3 may indicate some thyroid hormone production in patients off therapy for one month. In conclusion: Ectopic thyroid doesn't involuate during the 5 first years of life. Tg measurement is an efficient tool to evaluate remnant thyroid tissue if the patient are investigated under appropriate TSH stimulation.
